A pharmaceutical composition adapted for external application to human skin comprising a semi-solid carrier material containing zileuton dissolved or dispersed therein, and its use in the treatment of dermatological conditions.

A pharmaceutical composition adapted for external application to human skin comprising a semi-solid carrier material containing zileuton dissolved or dispersed therein, and its use in the treatment of dermatological conditions, particularly acne vulgaris, rosacea or atopic dermatitis.

The present invention provides methods of treating nasal polyps in cystic fibrosis patients using zileuton. The present invention also provides methods of treating nasal polyps in cystic fibrosis patients using zileuton in combination with surgical debridement and/or steroid treatment.

A crystalline form of (+)-R-zileuton, which may be used in pharmaceutical applications, is disclosed, characterized by a variety of properties and physical measurements. As well, methods of producing crystalline (+)-R-zileuton, and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of diseases, are also discussed.

Crystalline forms of (+)-R-zileuton which may be used in pharmaceutical applications are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well methods of producing crystalline (+)-R-zileuton and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of diseases are also discussed.

Crystalline forms of (+)-R-zileuton which may be used in pharmaceutical applications are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well methods of producing crystalline (+)-R-zileuton and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of diseases are also discussed.